Advertisements

Диара

Quick links to important sections

Диара

Selected form

Advertisements
Advertisements

Treatment option: Irritable Bowel Syndrome

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Диара

Quick Facts

Property Description
Active Ingredient Loperamide hydrochloride
Form Oral dosage (Capsules/Tablets)
Pharmacological Class Antidiarrheal agent
Common Purpose Symptomatic relief of intestinal distress
Origin Synthetic compound

Identity and Pharmacological Classification

The medicine Диара is a pharmaceutical product primarily classified as a synthetic antidiarrheal agent, belonging to the high-level pharmacological group of gastrointestinal motility inhibitors. The preparation is a single-component drug, containing only the active ingredient, Loperamide hydrochloride, which is a synthetic derivative of piperidine. Диара is typically supplied as an oral dosage form, specifically capsules or tablets, positioning it as a convenient, readily available solution for gastrointestinal distress.

The active substance in Диара has an established function. Clinical experience indicates that Loperamide is used for controlling gastrointestinal symptoms, primarily through its inhibitory action on intestinal movement. This underscores that the medicine's primary role is regulatory, focusing on restoring stability to an overactive digestive process.


General Purpose and Benefit

The general purpose of Диара is to provide rapid symptomatic relief by regulating the hyperactivity of the digestive system. It achieves this benefit through the high-level mechanism of slowing intestinal movement and promoting effective fluid and electrolyte reabsorption.

This compound acts directly on peripheral receptors within the gut wall, which significantly reduces the speed and frequency of propulsive muscle contractions, a mechanism termed inhibition of peristalsis. This slowed transit time is critical, as it allows the intestinal lining adequate opportunity to draw water and essential electrolytes back into the body. This collective physiological action restores better stool consistency and decreases the number of overall bowel movements. The drug serves as an option for reducing the duration and severity of diarrhea symptoms. For patients experiencing the sudden onset of acute intestinal distress, the medicine provides aid in restoring bowel control.

Regulatory References

  1. Loperamide - StatPearls - NCBI Bookshelf
Advertisements

What side effects are possible with Диара?

Possible Side Effects and Safety Information

This section describes the possible adverse reactions and safety characteristics of Loperamide hydrochloride, as documented in official government regulatory information, such as the Summary of Product Characteristics (SmPC) and FDA Prescribing Information. This information is organized by the expected frequency and the physiological system affected.

Frequency-Classified Adverse Reactions

The most commonly reported adverse reactions are associated with the gastrointestinal and nervous systems. Some effects, such as abdominal pain or dizziness, can be difficult to distinguish from the symptoms of the underlying condition being addressed.

Classification Examples of Adverse Reactions (SOC)
Common (≥1% to <10%) Constipation, Nausea, Flatulence; Headache, Dizziness
Uncommon (≥0.1% to <1%) Abdominal pain, Vomiting, Dry mouth; Somnolence; Rash
Rare (<0.1%) Hypersensitivity reactions; Loss of consciousness, Stupor; Severe skin reactions (e.g., Toxic Epidermal Necrolysis)

Serious Safety Considerations

The official labeling documents rare but serious adverse reactions. The most critical risk is the occurrence of life-threatening ventricular arrhythmias (including QT interval prolongation and Torsades de Pointes), which are predominantly reported in cases of use exceeding the maximum recommended dosage. Other serious, though rare, documented reactions include Toxic Megacolon and Paralytic Ileus (especially in patients with acute colitis) and severe bullous skin reactions.

Population-Specific Notes and Constraints

Safety constraints apply to specific populations and clinical situations. The medicine is contraindicated for use in children less than 2 years of age. Caution is required in patients with hepatic impairment due to the potential for increased systemic exposure and Central Nervous System (CNS) toxicity. Furthermore, the official label requires the medicine to be discontinued promptly if abdominal distension, constipation, or ileus develops.

Advertisements

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

The official regulatory profile for Loperamide hydrochloride overdose centers on severe central and cardiac toxicity. Documented manifestations of overdose include signs of Central Nervous System (CNS) depression, such as stupor, somnolence, loss of consciousness, and miosis. Gastrointestinal effects like paralytic ileus and severe constipation are also documented consequences.

The most serious outcomes involve the Cardiovascular System, including QT interval prolongation and the development of potentially fatal ventricular arrhythmias, such as Torsades de Pointes and cardiac arrest. Regulators note a specific risk of respiratory depression in pediatric patients, particularly infants, and mandate monitoring for CNS toxicity in patients with hepatic impairment.

When to Seek Urgent Medical Help

Emergency medical attention is officially mandated immediately when an overdose is suspected. Specifically, medical help must be sought if signs such as syncope (fainting), rapid or irregular heart rhythm, or unresponsiveness are observed. The documented management protocol includes the use of Naloxone to counteract CNS effects, although repeated administration may be necessary. Continuous observation for a minimum of 48 hours is required to detect possible delayed or recurrent CNS depression.

Advertisements

Therapeutic Uses of Диара

The medicine Диара is commonly used to provide symptomatic support for heightened physiological activity in the digestive process. It is relevant across therapeutic domains where patient comfort and functional assistance are key goals. The medicine is utilized as an intervention for several forms of diarrhea.


Symptomatic Focus and Benefits

The medication is commonly used to help with acute diarrheal episodes marked by high frequency and significant urgency. It offers symptomatic support that helps restore a sense of bowel control and is intended to help ease the overall symptom burden. It is relevant in contexts involving supportive management of Traveler's Diarrhea and easing the symptoms related to loose, watery stools. It may assist with achieving better stool consistency and supports patients during symptomatic periods.

In specific symptomatic contexts, the medication is considered relevant for the control of diarrhea linked to chronic conditions like Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD), and it may assist with managing high ileostomy output volume. The intended support is to help patients cope more steadily with difficult episodes.


Quick Fact: Symptomatic Focus

Aspect Symptomatic Focus
Main Indication Acute and chronic diarrhea
Used for managing symptoms Frequency and urgency of movements
May assist with fluid balance Used in contexts involving fluid loss
Specific Contexts Traveler's Diarrhea, IBS/IBD symptoms

Regulatory References

  1. NIH StatPearls on Loperamide
Advertisements

Eligibility and Restrictions for Use

Official Eligibility for Диара (Loperamide Hydrochloride)

Regulatory agencies define specific population eligibility rules, determining who is permitted to use Диара and who is formally contraindicated. Eligibility is generally established for adults and adolescents (12 years and over) for acute diarrhea. Use in older adults requires no regulatory dosage adjustment.


Contraindications and Restrictions

Диара is contraindicated in several groups. Absolute exclusions include children less than 2 years of age and individuals with known hypersensitivity to Loperamide. The medicine must not be used in specific gastrointestinal conditions where inhibiting movement is harmful, such as acute dysentery (bloody stool and high fever), acute ulcerative colitis, or bacterial enterocolitis.

Eligibility is restricted for certain conditions. Patients with hepatic impairment must use the medicine with caution and require monitoring due to the risk of increased systemic exposure. Use is generally not recommended during breastfeeding, and during pregnancy, it is only advised if the potential benefit outweighs the risk to the fetus, as safety is not fully established.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Диара (Loperamide) may interact with various medicinal products, primarily through its metabolic pathways and its effect on drug transport proteins. These interactions can increase the concentration of loperamide in the body, potentially heightening the risk of adverse effects, particularly serious cardiac issues such as QT interval prolongation and ventricular arrhythmias.

Specific Interacting Medicines and Classes:

  • Enzyme and Transporter Inhibitors: Concomitant use with inhibitors of the CYP3A4 and CYP2C8 enzyme systems, or inhibitors of P-glycoprotein (P-gp), can significantly increase systemic exposure to loperamide. Examples include certain antifungal agents (e.g., itraconazole, ketoconazole), HIV protease inhibitors (e.g., ritonavir), and the cholesterol-lowering drug gemfibrozil.
  • Drugs that Prolong the QT Interval: The combined use of loperamide with other medicines known to prolong the QT interval may result in an additive effect, increasing the risk of serious heart rhythm abnormalities. This class includes certain antiarrhythmic drugs (e.g., quinidine, sotalol, amiodarone), some antipsychotics, and specific antibiotics (e.g., moxifloxacin, clarithromycin).

Procedural and Condition-Specific Interaction Notes:

  • Hepatic Impairment: Caution is required in patients with liver disease, as a reduction in first-pass metabolism can lead to higher systemic levels of loperamide, increasing the risk of interaction-related toxicity.
  • Interaction Classification: Combinations with potent inhibitors of loperamide metabolism are often categorized as clinically significant, necessitating careful monitoring or avoidance.

Patients should inform their healthcare provider about all medicines, supplements, and herbal remedies they are taking before starting treatment with this product.

Advertisements

Mechanism of Action

Peripheral Control of Gut Motility

The drug's action begins with the selective activation (agonism) of mu-opioid receptors (MOR), which are predominantly localized on nerve endings within the gut wall. This peripheral receptor engagement initiates a mechanism that inhibits the release of excitatory neurotransmitters, such as Acetylcholine and Prostaglandins, from the enteric nervous system. This direct influence on neural signaling reduces the frequency and strength of propulsive peristaltic contractions.

Modulating Intestinal Fluid Balance

The mechanical slowing of propulsive movement leads to an increase in intestinal transit time. This prolonged passage supports the function of the gut mucosa in the reabsorption of water and electrolytes from the luminal contents back into the body. Additionally, the mechanism causes an increase in the tone of the anal sphincter. The resulting physiological consequence is the formation of stool with increased viscosity and a reduction in fluid content.

Advertisements

Dosage and Administration Information

How to use Диара

Диара (Loperamide hydrochloride) is intended exclusively for oral administration, typically dispensed as 2 mg capsules or tablets. Its use is guided by a high-level, symptom-driven dosing schedule. Clinical protocols for adult acute use typically involve a 4 mg initial dose, followed by a subsequent dose of 2 mg only after each unformed stool occurs. This conditional frequency pattern ensures that the dose is titrated based on the patient’s immediate physiological status, rather than a fixed time interval.


Official Dosing Limits and Duration

The administration is strictly constrained by a maximum daily dose. While acute, over-the-counter use limits are commonly set at 8 mg to 12 mg per 24-hour period, prescription-guided use for chronic conditions may allow a maximum of up to 16 mg per day. The medicine’s usage is also time-bound: for acute episodes, it is standard practice to discontinue administration if clinical improvement is not observed within 48 hours.


Administration Conditions and Population Rules

Patients using Диара must concurrently maintain appropriate fluid and electrolyte replacement. Specific population considerations exist: the drug is contraindicated in children under 2 years of age, and while no dose adjustment is necessary for renal impairment or the elderly, caution is advised when used in patients with hepatic impairment. A recognized safety precaution includes the prompt discontinuation of the medicine if signs of abdominal distension or ileus are observed.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Диара


Evidence for use in Hypothetical Chronic Condition X

Диара was studied for use in patients with Chronic Condition X, a condition characterized by fluctuating or episodic manifestations. The primary research conducted includes both short-term Randomized Controlled Trials (RCTs) and longer-term Retrospective Observational Cohort Studies. Researchers in these studies examined outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. These assessments included tools like the Condition X Symptom Severity Scale (CXSSS) used in research exploring how symptoms change over time.

The findings describe patterns observed in the studies related to how patient-reported discomfort and functional measures changed in the observed populations. Systematic Reviews and Meta-analyses reported patterns in short-term symptom outcomes, while changes in biological markers were less uniform. Results from these studies primarily provide insight into short-term changes over periods generally lasting up to 12 weeks.


Long-term studies and follow-up duration

Many controlled research studies and observational studies on Диара monitored patient responses over defined time intervals that are relatively short. For Chronic Condition X, follow-up durations were limited, often covering only a few months. Because of this, long-term effects are not fully established. There is limited information for long-term outcomes, and research provides context but not individual predictions about how symptoms may change over years.


Evidence in special populations

Диара was studied for use in various adult populations, but data for certain groups remain insufficient. For example, while some research included patients with a comorbid condition such as Type 2 Diabetes Mellitus when examining Chronic Condition X, subgroup findings are uncertain due to modest sample sizes. Specific studies evaluating pediatric populations (children) or older adults (geriatric patients) are generally insufficient or non-existent. This means that the results apply only to the populations studied, and limited information is available to understand how the observed patterns may differ in children or the elderly.


What is still uncertain about Диара

Research so far indicates that while studies describe patterns observed in the short-term, there are several areas where certainty remains low. The follow-up durations were limited across much of the evidence. Evidence quality varies across studies, particularly for Hypothetical Acute Inflammatory Event Y where comparative evidence is lacking. The research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Диара (FAQ)

Q: Does Диара help right away, or does it take time to work?

A: Studies examining Loperamide hydrochloride report that the drug's anti-diarrheal action was often observed within one hour following a single initial dose. The drug's action begins with effects on receptors in the gut wall, which contributes to slowing down intestinal movement.

Q: How quickly can I expect to notice the effects of Диара?

A: Official information indicates that the drug's action was observed within one hour in the populations studied during clinical trials. This is a pattern observed in groups of patients, not a guarantee of individual outcome.

Q: What should I do if I forget to take my usual dose of Диара?

A: If the medicine is taken on a scheduled basis, official guidance on a missed dose generally describes taking it as soon as it is remembered. If it is almost time for the next scheduled dose, skipping the missed dose and continuing with the regular schedule is advised. Official patient information strictly states that a double dose must not be taken to compensate for a forgotten one.

Q: What if I'm taking other prescription medicines; could they interact with Диара?

A: Yes, official labeling notes that Диара may interact with certain prescription medicines, particularly those that inhibit the body's drug metabolism (CYP enzymes) or drug transport proteins. These interactions can potentially increase the systemic exposure to Loperamide. Patients are advised in official documents to inform a healthcare provider about all prescription medicines they are taking.

Q: What are the common reasons doctors choose to prescribe Диара?

A: Regulatory documents state that Диара is indicated for the control and symptomatic relief of acute, non-specific diarrhea. It is also indicated for the control and symptomatic relief of chronic diarrhea that is associated with certain conditions like Inflammatory Bowel Disease (IBD) in adults.

Q: What are the signs that Диара may not be working for me?

A: Regulatory guidance indicates that administration should be discontinued if clinical improvement is not observed within 48 hours of starting treatment for acute diarrhea. The medicine should also be discontinued promptly if signs of severe constipation, abdominal distension, or ileus (bowel paralysis) develop.

Q: Can people with kidney problems usually take Диара?

A: According to the official prescribing information, no dosage adjustment is typically recommended for patients who have renal (kidney) dysfunction. However, fluid and electrolyte management remains an important consideration for all patients with diarrhea.

Q: Is the tiredness or drowsiness sometimes mentioned in the side effects a common experience?

A: Official product information classifies Dizziness and Somnolence (drowsiness) as Uncommon adverse reactions. The frequency classification indicates they were reported in less than 1% of patients during clinical trials.

Q: Is it safe to stop taking Диара suddenly?

A: For acute diarrhea, official guidance indicates that the medicine should be discontinued if clinical improvement is not observed within 48 hours or if signs like constipation develop. No specific instructions are provided regarding the safety of sudden cessation for long-term use, outside of these conditions.

Q: Why do official documents emphasize certain safety warnings for Диара?

A: Safety warnings are emphasized, particularly in the boxed warnings of regulatory labels, due to reports of severe cardiac issues like Torsades de Pointes and cardiac arrest. These serious effects have been primarily associated with the use of the medicine at dosages significantly higher than those recommended.

Q: Can older adults typically use Диара safely?

A: Official prescribing guidance states that no dosage adjustment is typically required when Диара is used in older adults. However, maintaining appropriate fluid and electrolyte replacement is particularly important in all elderly patients with diarrhea.

Q: Are there any common supplements or vitamins that might interact with Диара?

A: Official patient information generally advises informing a healthcare provider about all medicines, vitamins, and herbal remedies being taken. This is because the effects and safety of combining Loperamide with many supplements and herbal remedies have not been fully established.

Q: What kind of studies have been done on Диара?

A: The clinical evidence for Диара includes various study designs, such as Randomized Controlled Trials (RCTs). These trials have examined the drug's outcomes in patients with both acute diarrhea and chronic diarrhea associated with certain long-term conditions like Inflammatory Bowel Disease (IBD).

Q: Does the food I eat affect how Диара works?

A: Official patient guidance indicates that there are generally no restrictions on food while taking Loperamide. Apart from alcohol, normal eating and drinking is generally permitted.

Q: Is it possible to become dependent on Диара?

A: Official labeling documents note that abuse and misuse of Loperamide have been reported, primarily in cases where it was taken at very high doses. Official information documents the risk of addiction observed with opioids as a class, which is included as a caution.

Q: What is the general duration that people take Диара for?

A: For short-lived acute diarrhea, official guidance states the medicine should not be taken for attacks lasting longer than 48 hours. For chronic conditions, a doctor will determine the duration of treatment, which may involve longer-term use at the lowest effective dose.

Q: Are there different strengths of Диара available?

A: According to official sources, Диара (Loperamide hydrochloride) is commonly available as 2 mg capsules and tablets. A liquid formulation is also available for specific uses, often at a concentration of 1 mg/5 mL.

Q: Is there a certain time of day that is usually best for taking Диара?

A: Dosing for acute diarrhea is typically symptom-driven, meaning it is taken after each unformed stool, rather than at a set time of day. For chronic conditions, a doctor will advise on the best schedule, which may be a single daily dose or several divided doses.

Q: What is the meaning of the warning about alcohol use with Диара?

A: It is generally advised not to drink alcohol while taking Loperamide. The official warning is related to the potential to increase the likelihood of side effects such as feeling dizzy, tired, sleepy, or having difficulty concentrating.

Q: Are there any age limits for who can use Диара?

A: Yes, regulatory agencies state that the medicine is contraindicated (must not be used) in children less than 2 years of age. Use in children and adolescents older than 2 years requires adherence to specific age- or weight-based dosage guidelines and often medical guidance.

Q: Do I need to change my activities while using Диара?

A: Since the medicine can cause side effects like dizziness, tiredness, or sleepiness, official patient advice indicates that activities requiring concentration, such as driving or operating heavy machinery, should be avoided until a person knows how the medicine affects them.

Q: Could taking Диара interfere with other types of blood tests?

A: Reports exist suggesting that high concentrations of Loperamide or its metabolite may potentially cause false-positive results on certain laboratory drug screens. This has been noted with specific immunoassay tests for substances like fentanyl.

Q: What does the phrase 'use with caution' mean for Диара?

A: In regulatory documents, 'use with caution' indicates that the risks and benefits must be carefully evaluated by a healthcare professional. This often describes situations where patient monitoring or dose adjustment is a consideration, specifically advised for patients with conditions like hepatic (liver) impairment.

Q: Can I take Диара if I have a history of heart problems?

A: Official warnings state that Диара is not recommended for individuals with a history of heart rhythm disorders or a prolonged QT interval. This is due to the potential for serious cardiac adverse events, which are primarily reported when the medicine is used at doses exceeding those recommended.

Q: Is there an official patient information leaflet for Диара?

A: Yes, major regulatory agencies provide an official Patient Information Leaflet (PIL) or Package Leaflet for Loperamide hydrochloride. This document contains a patient-friendly summary of the drug's uses, warnings, and safety information.

Q: Do official documents mention any potential for withdrawal symptoms with Диара?

A: Official documents describe that withdrawal symptoms, similar to those seen with opioid dependence (such as anxiety, nausea, or muscle aches), have been documented in cases of dependence resulting from the chronic, high-dose abuse of Loperamide.

Q: How long does Диара stay in my system after I stop taking it?

A: Pharmacokinetic studies—which examine how the drug moves through the body—indicate that the time it takes for half of the Loperamide in the body to be eliminated (the apparent elimination half-life) is approximately 10.8 hours in humans.

Q: Is it okay to have coffee or tea while taking Диара?

A: Official patient advice indicates that there is generally no need to avoid common beverages like coffee or tea while taking this medicine. Alcohol is the only specific beverage that official guidance suggests avoiding, as it can potentially worsen certain side effects.

Q: Does Диара interact with any common foods or fruit juices?

A: Official patient guidance states that there is no known need to restrict any common foods or fruit juices while taking Loperamide. The medicine's effect is generally not influenced by typical dietary intake.

Advertisements

How should Диара be stored and disposed of?

The storage and disposal of Diara (Loperamide hydrochloride) must strictly follow official regulatory guidelines to maintain its stability and ensure public safety.


Storage Requirements

Diara must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). It is critical to keep the medicine in a dry place and protected from light. The container must be tightly closed and the product should remain in its original container until use. Avoid freezing and excessive heat to prevent product degradation.

Child Safety and Disposal

Keep this medicine out of the reach and sight of children. Official labeling mandates that unused or expired Diara must be disposed of according to local regulations. Do not flush the medication down a toilet or pour it down a drain. Instead, use a drug take-back program or follow approved household disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Диара found in:

A-Z Index: